275 related articles for article (PubMed ID: 32437331)
1. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.
Shrestha B; Walton K; Reff J; Sagatys EM; Tu N; Boucher J; Li G; Ghafoor T; Felices M; Miller JS; Pidala J; Blazar BR; Anasetti C; Betts BC; Davila ML
J Clin Invest; 2020 Sep; 130(9):4652-4662. PubMed ID: 32437331
[TBL] [Abstract][Full Text] [Related]
2. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease.
Wilson J; Cullup H; Lourie R; Sheng Y; Palkova A; Radford KJ; Dickinson AM; Rice AM; Hart DN; Munster DJ
J Exp Med; 2009 Feb; 206(2):387-98. PubMed ID: 19171763
[TBL] [Abstract][Full Text] [Related]
3. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.
Holtan SG; Savid-Frontera C; Walton K; Eaton AA; Demorest C; Hoeschen A; Zhang L; Reid K; Kurian T; Sayegh Z; Julia E; Maakaron J; Bachanova V; Jurdi NE; MacMillan ML; Weisdorf DJ; Felices M; Miller JS; Blazar BR; Davila ML; Betts BC
Clin Cancer Res; 2023 Mar; 29(6):1114-1124. PubMed ID: 36622700
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
Seldon TA; Pryor R; Palkova A; Jones ML; Verma ND; Findova M; Braet K; Sheng Y; Fan Y; Zhou EY; Marks JD; Munro T; Mahler SM; Barnard RT; Fromm PD; Silveira PA; Elgundi Z; Ju X; Clark GJ; Bradstock KF; Munster DJ; Hart DN
Leukemia; 2016 Mar; 30(3):692-700. PubMed ID: 26286117
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
7. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
8. CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.
Wong KY; Baron R; Seldon TA; Jones ML; Rice AM; Munster DJ
J Immunol; 2018 May; 200(10):3383-3396. PubMed ID: 29643191
[TBL] [Abstract][Full Text] [Related]
9. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
11. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
12. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
14. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
15. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
16. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cell therapy in AML: How close are we?
Gill S
Best Pract Res Clin Haematol; 2016 Dec; 29(4):329-333. PubMed ID: 27890255
[TBL] [Abstract][Full Text] [Related]
19. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
20. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
